Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences, Inc. director Dara Richardson-Heron reported receiving an option grant to purchase 45,000 shares of common stock. The option was awarded at an exercise price of $0.0000 per share, reflecting a typical compensatory equity award rather than an open-market transaction.
According to the vesting terms, one-twelfth of the shares subject to this option vest on each monthly anniversary of the February 20, 2026 grant date. The option will be fully vested by February 20, 2027, as long as Richardson-Heron continues to provide service to Caribou Biosciences through each monthly vesting date.
JOHNSON DAVID LEE reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director David Lee Johnson received a grant of 45,000 options to purchase common stock. The options were awarded for no cash consideration and are held directly by Johnson.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Johnson continues providing service to the company through each vesting date.
Caribou Biosciences, Inc. director Andrew Guggenhime received a grant of options to purchase 45,000 shares of the company’s common stock. The options were awarded at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date, so the entire 45,000-share option will be fully vested by February 20, 2027, as long as Guggenhime continues to provide services to the company through each vesting date.
Caribou Biosciences, Inc. reported that director Scott Braunstein received a grant of options to purchase 45,000 shares of common stock at an exercise price of $0.00 per share. One-twelfth of the options vest monthly and will be fully vested by February 20, 2027, assuming continued service.
Caribou Biosciences, Inc. Chief Financial Officer Sriram Ryali reported equity awards consisting of stock options and restricted stock units. He was granted an option to purchase 247,500 shares of common stock at an exercise price of $0.00 per share.
The option vests over time, with 1/48 of the shares vesting monthly so that it is fully vested by February 20, 2030, contingent on continued service. He also received 55,000 shares of common stock in the form of RSUs that vest in four equal annual installments beginning on February 20, 2027, also subject to continued service, and will be settled in stock within 30 days after each vesting date.
Haurwitz Rachel E. reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported new equity awards to President and CEO Rachel E. Haurwitz. On February 20, 2026, she was granted an option to purchase 682,500 shares of common stock and 151,700 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, the RSUs vest in four equal annual installments beginning on February 20, 2027, and are settled in stock within 30 days after each vesting date. The stock option vests as to 1/48 of the shares each month so that it is fully vested by February 20, 2030, in each case subject to her continued service.
The document also reports 3,369,395 shares of common stock held indirectly by The City Canyon Family Trust, of which she is a co-trustee with her spouse, in addition to directly held shares.
Caribou Biosciences (CRBU) filed its Q3 2025 10‑Q, showing licensing and collaboration revenue of $2.198 million and a net loss of $27.548 million for the quarter. For the nine months ended September 30, revenue was $7.218 million with a net loss of $121.637 million. Operating cash used year‑to‑date was $90.168 million.
Cash, cash equivalents, and marketable securities totaled $159.212 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company recorded $12.150 million of impairment charges and a $9.158 million impairment of an equity investment year‑to‑date, and reduced an MSKCC success payments liability to zero following license termination. Restructuring actions included discontinuing two programs and a workforce reduction of about 32%, with $1.8 million in severance and $0.4 million in wind‑down costs.
Clinical updates highlighted vispa‑cel (CD19): in a 22‑patient confirmatory cohort, overall response rate was 82% with a 64% complete response and 51% 12‑month progression‑free survival. An optimized 35‑patient cohort showed an 86% overall response and 63% complete response. The company plans a randomized pivotal phase 3 evaluation in second‑line LBCL.
Caribou Biosciences (CRBU) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025, and a business update. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act.
Caribou Biosciences (CRBU) reported preliminary cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025. The company also released new clinical data for its allogeneic CAR-T programs and outlined a pivotal plan for vispacabtagene regedleucel (vispa-cel).
In the ANTLER phase 1 trial’s 2L LBCL confirmatory cohort (N=22) with partial HLA matching and dosing at 80x10^6 cells, vispa-cel showed an 82% overall response rate (18/22), 64% complete response (14/22), and 51% 12‑month PFS at a 6.0‑month median follow-up. An optimized cohort (N=35) reported 86% ORR (30/35), 63% CR (22/35), and 53% 12‑month PFS at 11.8 months’ median follow‑up. Safety showed common TEAEs typical of CAR‑T; there were no GvHD cases, no grade ≥3 ICANS, fewer than 5% grade ≥3 CRS, and one vispa‑cel–related grade 5 IEC‑HS.
The company plans a randomized, controlled pivotal phase 3 in approximately 250 2L LBCL CD19‑naïve patients ineligible for transplant and autologous CAR‑T, with PFS as the primary endpoint. In multiple myeloma, CB‑011 dose escalation identified a recommended dose (450x10^6); in a 12‑patient BCMA‑naïve cohort at this dose, responses included 92% ORR (11/12), 75% CR/sCR (9/12), and 91% (10/11) MRD‑negativity at 8.3 months’ median follow‑up, with a manageable safety profile.
Caribou Biosciences (CRBU) reported preliminary cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025. The company also released new clinical data for its allogeneic CAR-T programs and outlined a pivotal plan for vispacabtagene regedleucel (vispa-cel).
In the ANTLER phase 1 trial’s 2L LBCL confirmatory cohort (N=22) with partial HLA matching and dosing at 80x10^6 cells, vispa-cel showed an 82% overall response rate (18/22), 64% complete response (14/22), and 51% 12‑month PFS at a 6.0‑month median follow-up. An optimized cohort (N=35) reported 86% ORR (30/35), 63% CR (22/35), and 53% 12‑month PFS at 11.8 months’ median follow‑up. Safety showed common TEAEs typical of CAR‑T; there were no GvHD cases, no grade ≥3 ICANS, fewer than 5% grade ≥3 CRS, and one vispa‑cel–related grade 5 IEC‑HS.
The company plans a randomized, controlled pivotal phase 3 in approximately 250 2L LBCL CD19‑naïve patients ineligible for transplant and autologous CAR‑T, with PFS as the primary endpoint. In multiple myeloma, CB‑011 dose escalation identified a recommended dose (450x10^6); in a 12‑patient BCMA‑naïve cohort at this dose, responses included 92% ORR (11/12), 75% CR/sCR (9/12), and 91% (10/11) MRD‑negativity at 8.3 months’ median follow‑up, with a manageable safety profile.
Caribou Biosciences (CRBU) reported preliminary cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025. The company also released new clinical data for its allogeneic CAR-T programs and outlined a pivotal plan for vispacabtagene regedleucel (vispa-cel).
In the ANTLER phase 1 trial’s 2L LBCL confirmatory cohort (N=22) with partial HLA matching and dosing at 80x10^6 cells, vispa-cel showed an 82% overall response rate (18/22), 64% complete response (14/22), and 51% 12‑month PFS at a 6.0‑month median follow-up. An optimized cohort (N=35) reported 86% ORR (30/35), 63% CR (22/35), and 53% 12‑month PFS at 11.8 months’ median follow‑up. Safety showed common TEAEs typical of CAR‑T; there were no GvHD cases, no grade ≥3 ICANS, fewer than 5% grade ≥3 CRS, and one vispa‑cel–related grade 5 IEC‑HS.
The company plans a randomized, controlled pivotal phase 3 in approximately 250 2L LBCL CD19‑naïve patients ineligible for transplant and autologous CAR‑T, with PFS as the primary endpoint. In multiple myeloma, CB‑011 dose escalation identified a recommended dose (450x10^6); in a 12‑patient BCMA‑naïve cohort at this dose, responses included 92% ORR (11/12), 75% CR/sCR (9/12), and 91% (10/11) MRD‑negativity at 8.3 months’ median follow‑up, with a manageable safety profile.
Caribou Biosciences reported a quarterly net loss of $54.1 million and a six-month net loss of $94.1 million, with licensing and collaboration revenue of $2.7 million for the quarter and $5.0 million for the six months ended June 30, 2025. Management reported cash, cash equivalents and marketable securities of $183.9 million as of June 30, 2025, which it expects will fund operations for at least the next 12 months.
The company announced a strategic pipeline prioritization that discontinues preclinical research and two programs (GALLOP and AMpLify) and reduced the workforce by 47 employees (~32%). It recorded $12.15 million of impairment charges and a $9.16 million impairment of its equity investment in Edge, remeasured the MSKCC success payments liability to zero following termination notice, and ended the quarter with total assets of $220.9 million and an accumulated deficit of $542.5 million.